Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/25/2018 |
| Start Date: | February 18, 2010 |
| End Date: | August 31, 2013 |
A Study Of Continuous Oral Dosing Of A Novel Antiandrogen Mdv3100, In Castration-resistant Bone Metastatic Prostate Cancer Patients Evaluating The Tumor Micro-enviroment
This study is being conducted to determine the effect of enzalutamide on the androgen
signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify
potential predictors of response or resistance to therapy.
signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify
potential predictors of response or resistance to therapy.
Inclusion Criteria:
- Confirmed prostate cancer
- Presence of metastatic disease to the bone
- Ongoing androgen deprivation therapy
Exclusion Criteria:
- Severe concurrent disease
- Metastases in the brain
We found this trial at
1
site
Click here to add this to my saved trials
